FrançaisAre analysts right about Tandem Diabetes Care (TNDM)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Tandem Diabetes Care, we replayed every analyst price target of the past 12 months and measured the real outcome: 30% were profitable, average return -5% (98 calls). At 3 months: +10% average return (42% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Raymond James | 12 | 33% | -14% |
| Piper Sandler | 10 | 30% | +31% |
| Citigroup | 8 | 12% | -12% |
| Wells Fargo | 8 | 12% | -36% |
| Barclays | 8 | 50% | -4% |
Frequently asked questions
Is Tandem Diabetes Care a buy right now?
The analyst consensus on Tandem Diabetes Care (TNDM) is "Buy" (14 bullish, 0 bearish calls over 12 months). This is not advice: historically, 30% of their targets on this stock turned out profitable over 1 year.
What is Tandem Diabetes Care's price target?
The median 12-month price target is $25.50 (+19% vs $21.40), ranging from $15.50 to $55.00 (12 analysts).
Are analysts accurate on Tandem Diabetes Care?
Over 1 year, 30% of analyst targets on Tandem Diabetes Care were profitable, for an average return of -5% (across 98 timestamped calls). This is JPI Invest's accuracy metric.
What is the Tandem Diabetes Care stock forecast?
Analysts target a median of $25.50 within 12 months, i.e. +19% vs the current price. The most bullish targets $55.00, the most cautious $15.50.
What is the Tandem Diabetes Care stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $25.50, +19%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (30%), and the stock's past trajectory.
Is Tandem Diabetes Care overvalued?
Detailed valuation data for Tandem Diabetes Care is available in the interactive analysis.
📊 See the full interactive analysis of Tandem Diabetes Care →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.